Publications by authors named "D Cattran"
Article Synopsis
- * In a study involving 947 children with IgAN, the revised tool outperformed the original in terms of model fit and predictive accuracy for 4-year outcomes, showing enhanced calibration and statistical values.
- * The findings indicated that kidney function (eGFR) trajectories were non-linear, with higher-risk children showing a faster decline, suggesting that the updated prediction should be used for ongoing risk assessment after one or two years following biopsy.
Background And Hypothesis: The MENTOR trial (MEmbranous Nephropathy Trial Of Rituximab) showed that rituximab was noninferior to cyclosporine in inducing complete or partial remission of proteinuria and was superior in maintaining proteinuria remission. However, the cost of rituximab may prohibit first-line use for some patients and health-care payers.
Methods: A Markov model was used to determine the incremental cost-effectiveness ratio (ICER) of rituximab compared with cyclosporine for the treatment membranous nephropathy from the perspective of a health-care payer with a lifetime time horizon.
Article Synopsis
- IgA nephropathy is a common kidney disease characterized by proteinuria, which signals a risk of kidney failure, and complement activation contributes to its progression.
- Cemdisiran, an experimental treatment that inhibits the production of a specific complement protein (C5), was evaluated in a study involving adults with IgA nephropathy to see if it could reduce proteinuria.
- The results showed that cemdisiran significantly reduced protein levels in urine and blood levels of C5, with mostly mild side effects, suggesting it may be a promising therapy for managing IgA nephropathy.
Evaluating Progression Risk in Patients With Immunoglobulin A Nephropathy.
Kidney Int Rep
December 2023
The highly variable rate of decline in kidney function in patients with immunoglobulin A nephropathy (IgAN) provides a major clinical challenge. Predicting which patients will progress to kidney failure, and how quickly, is difficult. Multiple novel therapies are likely to be approved in the short-term, but clinicians lack the tools to identify patients most likely to benefit from specific treatments at the right time.
View Article and Find Full Text PDFIntroduction: Kidney outcomes are improved in primary focal segmental glomerulosclerosis (FSGS) by maintaining a remission in proteinuria. However, characteristics associated with relapses are uncertain. We sought to identify these by analyzing each remission.
View Article and Find Full Text PDF